Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results
The objective of the study: to evaluate the efficacy and safety of treatment of tuberculosis patients with pre-extensive drug resistance and extensive drug resistance (XDR-TB) with regimen V using new anti-tuberculosis drugs including continuous treatment with bedaquiline.Subjects and methods. The t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2019-09-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1324 |
| _version_ | 1826563076061659136 |
|---|---|
| author | P. N. Golubchikov E. A. Kruk S. P. Mishustin T. I. Petrenko D. A. Kudlay |
| author_facet | P. N. Golubchikov E. A. Kruk S. P. Mishustin T. I. Petrenko D. A. Kudlay |
| author_sort | P. N. Golubchikov |
| collection | DOAJ |
| description | The objective of the study: to evaluate the efficacy and safety of treatment of tuberculosis patients with pre-extensive drug resistance and extensive drug resistance (XDR-TB) with regimen V using new anti-tuberculosis drugs including continuous treatment with bedaquiline.Subjects and methods. The treatment efficacy and safety were assessed in 39 patients treated with regimen V. Of them, 17 (43.6%) suffered from fibrous cavernous tuberculosis, 31 (79.5%), and 9 (23.1%) were HIV positive.Results. Treatment efficacy: 32 (82.0%) were cured, 1 (2.6%) was treatment failure, 4 (10.2%) did of non-tuberculosis, 2 (5.1%) defaulted from treatment. 23 (69.7%) patients took bedaquiline for the entire course of chemotherapy (the average duration made 19.3 months). Of them, 22 (95.6%) were cured, 1 (4.4%) had treatment failed. It was observed that the drug was well tolerated.Adverse events resulted in the cancellation of drugs were documented in 9 (23.1%) patients. After sputum conversion, 30 (76.9%) patients were treated using hospital-substituting technologies, including 10 of them who were treated under direct observation by video. Post-treatment follow-up is carried out in 28 out of 32 (2 changed their place of residence, 2 died of non-tuberculosis) of the treated patients, the average duration of follow-up have made 11.7 ± 6.3 months, the patients are relapse free. |
| first_indexed | 2024-03-12T03:30:17Z |
| format | Article |
| id | doaj.art-dda5b9c5533d40cf942556f71abb6a5d |
| institution | Directory Open Access Journal |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| last_indexed | 2025-03-14T09:58:12Z |
| publishDate | 2019-09-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj.art-dda5b9c5533d40cf942556f71abb6a5d2025-03-02T11:22:31ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062019-09-01978384510.21292/2075-1230-2019-97-8-38-451324Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed resultsP. N. Golubchikov0E. A. Kruk1S. P. Mishustin2T. I. Petrenko3D. A. Kudlay4Tomsk Phthisiopulmonology Medical CenterTomsk Phthisiopulmonology Medical CenterTomsk Phthisiopulmonology Medical CenterNovosibirsk Tuberculosis Research InstituteImmunology Research Institute by the Russian Federal Medical Biological AgencyThe objective of the study: to evaluate the efficacy and safety of treatment of tuberculosis patients with pre-extensive drug resistance and extensive drug resistance (XDR-TB) with regimen V using new anti-tuberculosis drugs including continuous treatment with bedaquiline.Subjects and methods. The treatment efficacy and safety were assessed in 39 patients treated with regimen V. Of them, 17 (43.6%) suffered from fibrous cavernous tuberculosis, 31 (79.5%), and 9 (23.1%) were HIV positive.Results. Treatment efficacy: 32 (82.0%) were cured, 1 (2.6%) was treatment failure, 4 (10.2%) did of non-tuberculosis, 2 (5.1%) defaulted from treatment. 23 (69.7%) patients took bedaquiline for the entire course of chemotherapy (the average duration made 19.3 months). Of them, 22 (95.6%) were cured, 1 (4.4%) had treatment failed. It was observed that the drug was well tolerated.Adverse events resulted in the cancellation of drugs were documented in 9 (23.1%) patients. After sputum conversion, 30 (76.9%) patients were treated using hospital-substituting technologies, including 10 of them who were treated under direct observation by video. Post-treatment follow-up is carried out in 28 out of 32 (2 changed their place of residence, 2 died of non-tuberculosis) of the treated patients, the average duration of follow-up have made 11.7 ± 6.3 months, the patients are relapse free.https://www.tibl-journal.com/jour/article/view/1324pulmonary tuberculosisextensive drug resistancetreatment with regimen vcontinuous treatment with bedaquiline |
| spellingShingle | P. N. Golubchikov E. A. Kruk S. P. Mishustin T. I. Petrenko D. A. Kudlay Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results Туберкулез и болезни лёгких pulmonary tuberculosis extensive drug resistance treatment with regimen v continuous treatment with bedaquiline |
| title | Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results |
| title_full | Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results |
| title_fullStr | Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results |
| title_full_unstemmed | Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results |
| title_short | Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results |
| title_sort | experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline in tomsk region immediate and postponed results |
| topic | pulmonary tuberculosis extensive drug resistance treatment with regimen v continuous treatment with bedaquiline |
| url | https://www.tibl-journal.com/jour/article/view/1324 |
| work_keys_str_mv | AT pngolubchikov experienceoftreatingextensivedrugresistanttuberculosispatientsincludingcontinuoususeofbedaquilineintomskregionimmediateandpostponedresults AT eakruk experienceoftreatingextensivedrugresistanttuberculosispatientsincludingcontinuoususeofbedaquilineintomskregionimmediateandpostponedresults AT spmishustin experienceoftreatingextensivedrugresistanttuberculosispatientsincludingcontinuoususeofbedaquilineintomskregionimmediateandpostponedresults AT tipetrenko experienceoftreatingextensivedrugresistanttuberculosispatientsincludingcontinuoususeofbedaquilineintomskregionimmediateandpostponedresults AT dakudlay experienceoftreatingextensivedrugresistanttuberculosispatientsincludingcontinuoususeofbedaquilineintomskregionimmediateandpostponedresults |